We are advising Esco Lifesciences on its Series A financing

Davis Polk is advising Esco Lifesciences in connection with its $200 million Series A financing. The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation, Singapore-based global investor EDBI, a reputable, long-term institutional investor, and other sophisticated investors.

Esco Lifesciences provides enabling technologies, products and services to the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing. Headquartered in Singapore, Esco Lifesciences has an extensive sales network in over 100 countries, direct sales and service offices in over 20 countries, eight manufacturing and R&D hubs in the United States, Europe, the United Kingdom, China, Singapore and over 1300 employees worldwide.

The Davis Polk corporate team includes partner Yang Chu, associate Jessica Ng and registered foreign lawyer Michael Zhuoran Xu. All members of the Davis Polk team are based in the Hong Kong office.